Investigating the role of Interferon E in pancreatic cancer treatment
Official title: Interferon E as a Tumor Suppressor and Potential Therapeutic in Pancreatic Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11070938 · Data updated 2026-11-12
This study is looking at how a gene called Interferon E might help fight pancreatic cancer by stopping tumors from growing and spreading, and it will also test if using this gene in a special way could boost the immune system to better attack the cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 28, 2025 |
| Project end | March 27, 2028 |
| Funding year | 2025 |
| Award (this year) | $49,538 |
| NIH project number | 1F31CA290899-01A1 |
| Project ID | NIH-11070938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with specific genetic profiles related to the 9p21.3 deletion.
✕Less likely to help
Patients with other types of cancer or those without the relevant genetic markers may not benefit from this research.
What this research studies
This research focuses on understanding how a specific gene, Interferon E, can act as a tumor suppressor in pancreatic cancer. The study will explore the effects of deleting this gene in mouse models of pancreatic ductal adenocarcinoma (PDAC) to see how it influences tumor growth, metastasis, and the immune response. Additionally, the research will test the potential of using recombinant Interferon E as a therapeutic option to enhance immune surveillance against tumors. By examining these factors, the research aims to uncover new strategies for improving treatment outcomes for patients with pancreatic cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance the immune system's ability to fight pancreatic cancer.
How similar studies have gone: Previous research has shown promising results in targeting immune responses in cancer, suggesting that this approach could be effective, although the specific focus on Interferon E in pancreatic cancer is relatively novel.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Del Priore, Isabella — Sloan-Kettering Inst Can Research
- Study coordinator: Del Priore, Isabella
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.